Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

证券代码：603122 证券简称：合富中国 公告编号：临2025-040 合富（中国）医疗科技股份有限公司 关于2025年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"、"合富中国"或"合富"）于2025年10月16日（星 期四）11:30-12:30在价值在线网站（https://www.ir-online.cn/）通过网络文字互动的形式召开了公司2025 年半年度业绩说明会，现将具体情况公告如下： 一、本次业绩说明会召开情况 公司于2025年10月16日（星期四）11:30-12:30召开了公司2025年半年度业绩说明会，董事长 李惇先 生、董事 总经理 财务总监王琼芝女士、独立董事 蔡彦卿先生、独立董事 翁文能先生、董事会秘书 朱 莺女士出席了本次业绩说明会，与投资者进行网络互动交流和沟通。本次业绩说明会召开前，公司已通 过公司投资者关系邮箱ir_cowealth@cowealth.com进行了提问预征集。 二、投资者提问及公司回复情况 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-040 合富（中国）医疗科技股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"、"合富中国"或"合 富 "） 于 2025 年 10 月 16 日 （ 星 期 四 ） 11:30-12:30 在 价 值 在 线 网 站 （https://www.ir-online.cn/）通过网络文字互动的形式召开了公司 2025 年半 年度业绩说明会，现将具体情况公告如下： 一、本次业绩说明会召开情况 公司于 2025 年 10 月 16 日（星期四）11:30-12:30 召开了公司 2025 年半年 度业绩说明会，董事长 李惇先生、董事 总经理 财务总监王琼芝女士、独立董 事 蔡彦卿先生、独立董事 翁文能先生、董事会秘书 朱莺女士出席了本次业绩 说明会，与投资者进行网络互动交流和沟通。本次业绩说明会召开前，公司已通 过公司投资者关系邮箱 ir_cowealth ...

Core Viewpoint - The company, HeFu China, reported a significant decline in consolidated revenue for the first nine months of the year, indicating potential challenges in its business performance [1] Financial Performance - The consolidated revenue for HeFu China from January to September reached 549 million yuan, which represents a 22.8% decrease compared to the same period last year [1]

合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-9 月合并营业收入人民币 54,886.23 万元，较去年同期下降 22.80%。 2025 年 1-9 月累计营业收入简报 2025 年 10 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 特此公告。 证券代码：603122 证券简称：合富中国 公告编号：临 2025-039 合富（中国）医疗科技股份有限公司董事会 合富（中国 ...

格隆汇10月13日丨合富中国(603122.SH)公布，公司2025年1-9月合并营业收入人民币5.49亿元，较去年 同期下降22.80%。 ...

合富中国公告，公司2025年1-9月合并营业收入5.49亿元，较去年同期下降22.80%。该数据为初步核 算，未经会计师事务所审计或审阅，最终以公司定期报告为准。 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-038 合富（中国）医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 价值在线网站 https://www.ir-online.cn 一、说明会类型 合富（中国）医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》 及《2025 年半年度报告摘要》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况等，公司计划于 2025 年 10 月 16 日（星期四） 价值在线网站 https://www.ir-online.cn 3、召开方式：网络文字互动 三、参会人员： 公司出席本次说明会的人员：董事长 李惇先生、董事 总经理 财务总监王 琼芝女士、独立董事 蔡彦卿先生、董事会秘书 朱莺女士（如遇特殊情况，参加 人员可能进行调整）。 会议召开时间：2025 年 ...

Market Overview - On September 25, the pharmaceutical commercial sector declined by 1.06%, with HeFu China leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable stock performances include: - N Jianfa Zhi (301584) surged by 418.58% to a closing price of 36.56, with a trading volume of 419,500 shares and a transaction value of 1.477 billion [1] - Jia Shi Tang (002462) increased by 6.61% to 14.51, with a trading volume of 193,500 shares and a transaction value of 279 million [1] - HeFu China (603122) fell by 4.69% to 6.51, with a trading volume of 169,000 shares and a transaction value of 112 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 337 million from institutional investors, while retail investors experienced a net outflow of 591 million [2] - Key capital flows for selected stocks include: - N Jianfa Zhi (301584) had a net inflow of 45.716 million from institutional investors, accounting for 30.94% of its total [3] - Jia Shi Tang (002462) recorded a net inflow of 51.35 million from institutional investors, representing 18.43% [3] - HeFu China (603122) experienced a net outflow of 16.49 million from retail investors, which is -43.96% of its total [3]